Windtree Therapeutics Inc (WINT)

Total Shares Outstanding (millions) = 12

https://www.nasdaq.com/market-activity/stocks/wint/institutional-holdings

=============================

Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure

July 12, 2025

1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old

If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039

WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.”

About Windtree Therapeutics, Inc.Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue generating company in a multitude of growing industries to drive toward overall profitability.

https://www.nasdaq.com/press-release/windtree-announces-issuance-istaroxime-patent-united-states-acute-heart-failure-2025

$WINT

WINT.....................................................................................p/m

Nice pre market action 💹 this morning!

$WINT

WINT...99...🥳...70 Million Voluem off yesterdays News... https://finviz.com/news/94148/windtree-announces-issuance-of-istaroxime-patent-for-the-united-states-for-acute-heart-failure

WINT...............................p/m

$WINT 💹

Very wide target range from low $4 tot high $367.50 ? 😆 LOL

========================

Price Target
The average one-year price target for Windtree Therapeutics, Inc. is $180.54. The forecasts range from a low of $4.04 to a high of $367.50. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.

Update Frequency: Monthly

https://fintel.io/s/us/wint

========================

According to the 1 analysts' twelve-month price targets for Windtree Therapeutics, the average price target is $350.00. The highest price target for WINT is $350.00, while the lowest price target for WINT is $350.00. The average price target represents a forecasted upside of 45,354.55% from the current price of $0.77.

https://www.marketbeat.com/stocks/NASDAQ/WINT/forecast/

$WINT

Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure
1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients >65 years old

If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039

WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.”

Acute heart failure, or AHF, impacts millions of patients globally and istaroxime has previously completed two positive Phase 2 AHF studies and two positive early cardiogenic shock studies caused by acute heart failure.

“We are pleased to strengthen our intellectual property for istaroxime with this patent for the United States,” said Jed Latkin, CEO of Windtree. “Istaroxime is approaching Phase 3 readiness in cardiogenic shock and acute heart failure. If istaroxime is approved in AHF, this patent would provide protection until 2039. We believe the profile of istaroxime is differentiated from currently available drugs and drug treatment innovation is desired for patients.”

About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances.

WINT...............................................................p/m

wint.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Dilution might have or be ending,chart shows bullish start,shares to short dropped from 150k to 15k @ 8am,back up to 80k now,could drop to zero borrow next,death hr ending in 30min. Could see volume surge and run as it’s trading freely today,big risk big reward with this low float,trade accordingly I am in .38 and bids in for more if it dips

Are they going to request a hearing?

Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business
Windtree continues its transformation entering the rapidly growing $85 billion US environmental services space

Refocused strategy is expected to generate $12 million in revenue over the next 12 months

Transaction expected to produce a profitable business with growth opportunities through a roll up strategy

Windtree continues to pursue partnership or sale of pharmaceutical assets to reduce costs

WARRINGTON, Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, today announced a significant step in its drive toward overall profitability through its entry into a binding agreement to acquire Titan Environmental Services, Inc. (“Titan”)(OTC: TESI), a waste management business with operations in Michigan.

As consideration for the transaction, Windtree will issue preferred shares and has secured debt financing to fund the transaction and working capital for the business. Titan Environmental Services will become Windtree Environmental Services (“Windtree Environmental”) and operate as a subsidiary of Windtree. Members of Titan’s current management team will be retained to leverage their extensive experience in the waste management industry. The transaction is expected to close in the 3rd quarter. In the event an agreement cannot be consummated, the Company is entitled to an $8.0 million breakup fee.

Over the last several months, Titan has undergone changes to its management and strategy, eliminating non-core assets, in order to focus on its waste management expertise to drive revenue. The United States waste collection market was valued at $85 billion in 2024 and has historically generated attractive EBITDA margins and free cash flow. In addition to the acquisition of Titan, the Company believes the fragmented waste management market may provide an opportunity to scale the business and provide additional top-line revenue growth and positive EBITDA contributions through additional acquisitions. Windtree Environmental intends to immediately begin the implementation and execution of a roll-up strategy to capitalize on this opportunity.

Under Windtree’s refined corporate strategy, the Company has, and continues to, pursue opportunities in a multitude of growing industries to drive toward overall profitability. The Company continues to evaluate options for its drug candidate pipeline in an effort to reduce costs and increase overall profitability.

“This transaction strategically aligns with our vision of diversifying our business model by increasing revenue and providing significant growth potential for the Company,” said Jed Latkin, Chief Executive Officer of Windtree. “We look forward to working with the Titan management and continuing to execute on our refined corporate strategy.”

About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company focused on becoming a revenue-generating company in a multitude of growing industries to drive toward overall profitability.

WINT..............................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT, 10Q due Thursday 4/17

Did somebody mention rveginas ?

$WINT: Who doesn't love Vaginal News

Am I right Ladies ???


GO $WINT

WINT...................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Vaginal news followed up by compliance news this morning  $3.55 + 40% . Be wise low float 800k but offering comes eventually 

WINT.......................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

Power hour...wint at 2.16...will it get pumped at eod??

$WINT: We're going to $5 before EOD

You heard it here first....................... Don't be scared now


GO $WINT

$WINT; $3.40 babyyyyyyyyyyyyyyyyyyyyyyyyy

Whos havin a good time............ talk to me now


GO $WINT

$WINT: Bring on the $3 breaker baby


You know you wannnnaaaaaaaaaaaaaaaaaaaaaaaa

Do it for DADDY


GO $WINT

$WINT: Now 2.70 ....................

Holla back if you making money off my CALLOUTS !!!!!!!!!!!!!!!

Love to hear from you.

Keep on ROcking in the Free World............ while its still a Free World




GO $WINT

WINT.........................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

$WINT: Going on News...............




GO $WINT

$WINT: The bottom is in............ look at 200day chart

Shes gonna get to $3 today

GO $WINT

$WINT: BOoommmmmmmmmmmm.... now $2.20

Thar she blowwwwwwwwwssssssssssssss


GO $WINT

WINT........................................................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

WINT EXPLOSION

WINT POST SPLIT MOVE

WINT, new 52 week low

RS info -1 for 50- feb 20--Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, announces that its board of directors has approved a 1-for-50 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on February 3, 2025. The stockholders granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
The reverse stock split will become effective on February 20, 2025 at 5:00 p.m., Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) on February 21, 2025 at market open under the existing ticker symbol, “WINT.” The reverse stock split is intended to increase the price per share of the Company’s common stock to allow the Company to demonstrate compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq, among other benefits.

big uptick on GNS also 😅

nice move 😁

WINT.............................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783

.2530 + 58%

Jumped in today .125 heavy

great site- thanks RS 5 to 50 Vote Approved

Scroll 9 down...https://dilutiontracker.com/app/reverse-split

RS approved- no ratio announced yet

$WINT Hmm reversal here starting? Maybe run before 2/3 meeting.

checked for reason on surge and nothing visible, even on website

today announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a well-received presentation highlighting the data on istaroxime from the recently completed Phase 2b SEISMiC B study in early cardiogenic shock due to heart failure. The presentation was given at the Cardiovascular Clinical Trials Conference in Washington, DC.

Dr. Alexandre Mebazaa is Professor of Medicine at Université Paris Cité (France), Chair of Department of Anesthesia & Critical Care and an expert in heart failure and cardiogenic shock. He is part of the task force that wrote the 2021 ESC/HFA Guidelines of Heart Failure and the 2023 addendum.

WINT, new 52 low

WINT 10Q due 11/11

Took another position here, this could very easily be a $30.00 stock in 2 years, patience pays.

Ping pong .80s to $1s

This may be the bottom for a longer term play,if they are successful with phase three it will be a $30.00 +/- stock. IMO

WINT.....................................https://stockcharts.com/h-sc/ui?s=WINT&p=W&b=5&g=0&id=p86431144783